Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EOS301984 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A dose escalation | EXPERIMENTAL | EOS301984 dose escalation as monotherapy |
| Part 1B dose escalation | EXPERIMENTAL | EOS301984 in combination with other cancer therapies |
| Name | Type | Description |
|---|---|---|
| EOS301984 | DRUG | Multiple doses of EOS301984 |
| Anti-PD-1 monoclonal antibody | DRUG | Multiple doses of EOS301984 in combination with Anti-PD-1 |
INCLUSION CRITERIA * Provide a signed written informed consent before any study-specific evaluation. * Be at least 18 years old on the day of signing informed consent. * Have a histologically confirmed advanced solid tumor for which no standard approved treatment is available, or are ineligible for...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
EOS301984 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development as a potential therapy for adult patients with advanced solid tumors.
EOS301984 targets PD-1, a protein involved in immune checkpoint regulation. By targeting PD-1, the drug is designed to modulate the immune system's response to cancer cells, though its full mechanism of action is still under investigation.
EOS301984 is being developed by iTeos Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ITOS. The company is conducting a first-in-human study of the drug in advanced solid tumors.
EOS301984 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is a first-in-human study evaluating the drug as monotherapy or combination therapy.
EOS301984 is being studied in a Phase 1 clinical trial with the identifier NCT06547957. This first-in-human study is evaluating the drug as monotherapy or combination therapy in adult participants with advanced solid tumors, with an enrollment of 55 participants.
EOS301984 is a unique investigational compound developed by iTeos Therapeutics. No alternative names for this drug have been reported in the available clinical trial information.